BACKGROUND
■ iX Biopharma focuses on the development and commercialisation of innovative therapies for pain management and male erectile dysfunction. The group currently has three drugs under development - WafermineTM, WafernylTM and PheoniXTM, and operates an integrated business model encompassing drug development, manufacturing and supply.
BUSINESS STRATEGY AND FUTURE PLANS
■ Develops and commercialises its products to gain market share in Australia and other parts of the world.
■ Expands portfolio of products by developing a pipeline of products incorporating proprietary drug delivery technology to address unmet or under-served therapeutic needs.
■ Collaborates with third parties to expand product reach into other geographical regions.
Read more »